OTCMKTS:NRIFFNuvo Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nuvo Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.52 0.00 (0.00 %) (As of 07/13/2020 08:55 AM ET) Add Compare Share Today's Range$0.52Now: $0.52▼$0.5250-Day Range$0.51MA: $0.56▼$0.6052-Week Range$0.24Now: $0.52▼$0.87VolumeN/AAverage Volume3,449 shsMarket Capitalization$5.93 millionP/E Ratio13.00Dividend YieldN/ABeta1.51 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Nuvo Pharmaceuticals Inc., a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nuvo Pharmaceuticals. Previous Next 2.4 Community Rank Outperform VotesNuvo Pharmaceuticals has received 44 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNuvo Pharmaceuticals has received 49 “underperform” votes. (Add your “underperform” vote.)Community SentimentNuvo Pharmaceuticals has received 52.69% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nuvo Pharmaceuticals and other stocks. Vote “Outperform” if you believe NRIFF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NRIFF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNuvo Pharmaceuticals does not currently pay a dividend.Dividend GrowthNuvo Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvo Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvo Pharmaceuticals is 13.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvo Pharmaceuticals is 13.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.22.Price to Book Value per Share RatioNuvo Pharmaceuticals has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.86 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NRIFF Previous Symbol CUSIPN/A CIKN/A Webwww.nuvopharmaceuticals.com Phone905-673-6980Debt Debt-to-Equity Ratio5.11 Current Ratio2.57 Quick Ratio2.09Price-To-Earnings Trailing P/E Ratio13.00 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$52.41 million Price / Sales0.11 Cash Flow$0.85 per share Price / Cash Flow0.61 Book Value$1.59 per share Price / Book0.33Profitability EPS (Most Recent Fiscal Year)N/A Net Income$2.53 million Net Margins17.41% Return on Equity4.76% Return on Assets0.66%Miscellaneous Employees97 Outstanding Shares11,400,000Market Cap$5.93 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable OTC:NRIFF Rates by TradingView Receive NRIFF News and Ratings via Email Sign-up to receive the latest news and ratings for NRIFF and its competitors with MarketBeat's FREE daily newsletter. Nuvo Pharmaceuticals (OTCMKTS:NRIFF) Frequently Asked Questions How has Nuvo Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Nuvo Pharmaceuticals' stock was trading at $0.6007 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NRIFF shares have decreased by 13.4% and is now trading at $0.52. View which stocks have been most impacted by Coronavirus. When is Nuvo Pharmaceuticals' next earnings date? Nuvo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Nuvo Pharmaceuticals. How were Nuvo Pharmaceuticals' earnings last quarter? Nuvo Pharmaceuticals Inc (OTCMKTS:NRIFF) issued its quarterly earnings results on Monday, May, 11th. The company reported $0.12 earnings per share (EPS) for the quarter. The business had revenue of $18.16 million for the quarter. Nuvo Pharmaceuticals had a net margin of 17.41% and a return on equity of 4.76%. View Nuvo Pharmaceuticals' earnings history. Has Nuvo Pharmaceuticals been receiving favorable news coverage? Press coverage about NRIFF stock has trended very negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nuvo Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Nuvo Pharmaceuticals. Who are some of Nuvo Pharmaceuticals' key competitors? Some companies that are related to Nuvo Pharmaceuticals include OHR Pharmaceutical (OHRP), IntelGenx Technologies (IGXT), IMMURON LTD/S (IMRN), Eyegate Pharmaceuticals (EYEG), Cyclacel Pharmaceuticals (CYCC), Iterum Therapeutics (ITRM), Ritter Pharmaceuticals (RTTR), Nemus Bioscience (NMUS), Salarius Pharmaceuticals (SLRX), Intec Pharma (NTEC), Provectus Biopharmaceuticals (PVCT), Uluru (ULUR), Adial Pharmaceuticals (ADIL), OTCMKTS:EMBI (EMBI) and Bio-Path (BPTH). View all competitors. Who are Nuvo Pharmaceuticals' key executives? Nuvo Pharmaceuticals' management team includes the following people: Mr. Robert Paul Harris, Exec. Chairman (Age 64)Mr. Jesse F. Ledger, Pres & CEOMs. Mary-Jane E. Burkett CPA-CA, HBA, VP & CFOMs. Katina K. Loucaides M.Sc., LL.B, VP, Corp. Sec. & Gen. CounselMr. Calogero Lunetta MSc, VP of Manufacturing What is Nuvo Pharmaceuticals' stock symbol? Nuvo Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NRIFF." How do I buy shares of Nuvo Pharmaceuticals? Shares of NRIFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nuvo Pharmaceuticals' stock price today? One share of NRIFF stock can currently be purchased for approximately $0.52. How big of a company is Nuvo Pharmaceuticals? Nuvo Pharmaceuticals has a market capitalization of $5.93 million and generates $52.41 million in revenue each year. Nuvo Pharmaceuticals employs 97 workers across the globe. What is Nuvo Pharmaceuticals' official website? The official website for Nuvo Pharmaceuticals is www.nuvopharmaceuticals.com. How can I contact Nuvo Pharmaceuticals? Nuvo Pharmaceuticals' mailing address is 6733 MISSISSAUGA ROAD SUITE 610, MISSISSAUGA A6, L5N 6J5. The company can be reached via phone at 905-673-6980 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
